Aim Immunotech Inc (AIM)

$2.34 0.01 (0.43%)

20:00 EST AIM Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 988,900

Day's Range 2.28 - 2.37

52-Week Range 1.35 - 7.41

Dividend & Yield N/A (N/A)

AIM Stock Predictions, Articles, and Aim Immunotech Inc News

From InvestorPlace
From the Web

7 Biotech Stocks Focused on Chronic Covid Treatment

By Thomas Niel Feb 22, 2021

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today

By William White, InvestorPlace Writer Sep 22, 2020

Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher.

AIM ImmunoTech Seduces With Coronavirus Treatment Potential

By Todd Shriber, InvestorPlace Contributor Jul 17, 2020

One of the things that's been keeping interest in AIM somewhat strong since that March plunge is that no company has pinned down an effective coronavirus treatment or vaccine. It's not a stretch to say some ambitious, risk-tolerant investors may be looking at AIM through the lens of the “door's open, why not AIM?”

2 Pros, 2 Cons for Buying AIM ImmunoTech

By Josh Enomoto, InvestorPlace Contributor Jun 17, 2020

AIM stock has entered Wall Street’s consciousness due to the underlying biotech firm’s potential coronavirus treatment. However, will this be enough to keep shares moving higher?

Coronavirus Research Is the Key for AIM ImmunoTech Stock

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Jun 15, 2020

One big breakthrough moment in coronavirus research could bring wealth to AIM ImmunoTech. It could also bring big gains to AIM stock.

AIM Stock Is a Moonshot That Lacks the Fuel

By Chris Markoch Apr 9, 2020

Though AIM stock is relevant on paper, with competition raging in the race for a coronavirus treatment, along with AIM ImmunoTech's checkered past, this is a very speculative gamble.

Don’t Pull the Trigger on AIM ImmunoTech Stock

By Chris Tyler, InvestorPlace Contributor Apr 2, 2020

If it sounds too good to be true, it probably is. And that's likely the case when you look deeper into what's going on with AIM ImmunoTech stock.

AIM Stock: You’ve Got a Better Shot of Getting Rich Buying a Lottery Ticket

By Will Ashworth, InvestorPlace Contributor Apr 2, 2020

AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.

Read the Label Before Buying AIM Stock

By Josh Enomoto, InvestorPlace Contributor Mar 27, 2020

One of the few sectors that have enjoyed upside is the pharmaceutical industry. In particular, AIM stock has jumped on a possible Covid-19 treatment. Nevertheless, you want to look carefully at the label before jumping aboard.